The low-code/no-code approach accelerates the design and deployment of eCOA questionnaires, eliminating questionnaire creation, licensing and localization from the critical path.
Suvoda , a global clinical trial technology company specializing in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare diseases, announced the receipt of a patent from the U.S. Patent Office for the Suvoda Questionnaire Definition Language (SQDL), which is part of the software architecture of its electronic clinical outcomes assessment (eCOA) product.
The patent demonstrates the power of Suvoda’s eCOA solution: accelerating questionnaire creation, translation, localization and deployment so clinical trial sponsors can launch their studies more efficiently. While eCOA has traditionally been a bottleneck in clinical trial implementation, Suvoda’s eCOA and its SQDL tool enable sponsors to deliver high-quality questionnaires in hours, instead of days.
“This recognition by the U.S. Patent Office is a testament to our team’s ingenuity, creativity and technical excellence. Many claim to offer similar capabilities, but Suvoda’s patented technology allows us to deliver on our promise. Suvoda eCOA accelerates questionnaire implementation in compliance with regulations, which is critical to the efficiency and success of clinical trials,” said Jagath Wanninayake, CEO of Suvoda.
Also Read: Agilent Launches Mito-rOCR Assay Kit for Mito Research
The patented architecture offers several key advantages:
- Easy eCOA Questionnaire Creation : Suvoda’s eCOA enables non-engineers to define eCOA questionnaires using a simple, no-code approach while maintaining strict regulatory compliance. It includes a real-time preview of each question, language, and layout configuration to improve feedback and productivity.
- Accelerated development through parallel processing : questionnaire definition, licensing, translation and layout are done simultaneously and are decoupled from study development.
Localization partners work directly in Suvoda’s eCOA, previewing translations in real-time and minimizing back-and-forth with Suvoda and the sponsor. - Simplified mid-study questionnaire update : Questionnaires can be easily modified while maintaining the validated state of the eCOA system, so that changes during the study do not delay data collection.
- Efficient questionnaire and component reuse: Suvoda’s eCOA allows questionnaires to be stored and reused, when permitted, in an accessible and organized manner, and ensures compatibility with newly updated devices without affecting system validation.
“The SQDL architecture fundamentally changes the way eCOA questionnaires are created by enabling parallel construction of translations and layouts. We have patented the core of our business, supporting a powerful no-code/low-code definition layer that enables an ecosystem of tools – such as real-time, accurate device previews and screenshot generation – that can improve eCOA implementation and deployment,” explained Andrew McVeigh , Chief Architect at Suvoda.
Suvoda’s eCOA is part of a comprehensive suite of clinical trial solutions, including Interactive Response Technology (IRT), eConsent and the recently launched ePatient. Unified on the Suvoda technology platform, these products support clinical trial sponsors at the most critical moments in their studies, enabling them to improve operational efficiency, reduce site burden, transform the patient journey and contribute to the advancement of human health.
Source: PRNewswire